How Hormone Pellets Provide Steady Hormone Levels: EvexiPEL Science

Dr. Crystal Broussard, MD

Board Certified in Family Medicine  ·  Specialized training in Obesity Medicine

Understanding the Hormone Pellet Delivery System: How Subcutaneous Release Works

Questions about the hormone pellet delivery system come up frequently in my practice. Patients want to know: do pellets really provide steadier hormone levels, and is there science behind the claim? The short answer is that yes, a foundational pharmacokinetic study—Jockenhövel et al., published in Clinical Endocrinology (Oxford) in 1996—demonstrated that subcutaneous testosterone implants in hypogonadal men produced an initial brief peak followed by a measurable plateau phase, with a gradual decline after approximately two months. That research has shaped how we understand pellet kinetics, but it was conducted in 50 men using a specific pellet dose and reflects the evidence as it stood 30 years ago. As Dr. Crystal Broussard, MD—Board Certified in Family Medicine and Fellow of the American Board of Obesity Medicine, specializing in Obesity Medicine, I evaluate hormone therapy through the lens of each patient’s complete metabolic and clinical picture—not as a preset solution.

This article covers what the research actually shows about subcutaneous hormone release kinetics, how pellet delivery differs from other methods, the important regulatory context that every patient should understand, and what a thorough evaluation looks like before any hormone therapy is initiated. Pellets are compounded formulations that are not FDA-approved, and the decision to use them should always involve an honest informed consent discussion about their advantages, limitations, and the professional society guidance that shapes how responsible physicians approach this option.

Important Safety Information

Hormone pellet therapy is not appropriate for everyone. Patients with a history of hormone-sensitive cancers, unexplained vaginal bleeding, active or prior blood clots, or certain cardiovascular conditions should not use pellet therapy. The insertion procedure carries risks including infection at the implantation site, pellet extrusion, bleeding, and local site reactions. Because pellets cannot be easily removed once inserted, any adverse reaction to the hormone itself requires managing symptoms for the duration of the pellet’s activity. Pregnant or breastfeeding women should not use hormone pellets. All patients considering pellet therapy should undergo comprehensive lab work, a thorough health history review, and commit to ongoing monitoring. This article is for educational purposes only and does not constitute medical advice—consultation with a qualified physician is essential before starting any hormone therapy.

The Science Behind Subcutaneous Hormone Release

Hormone pellets are small, rice-sized cylinders of compressed bioidentical hormone—typically testosterone or estradiol—inserted under the skin in the hip or buttock area through a minor in-office procedure. Once implanted, body heat and moisture cause the pellet to dissolve gradually over time, releasing hormone into the surrounding tissue where it can be absorbed into the bloodstream. Patient education resources including Mayo Clinic 2024 describe this insertion and re-pellet cycle as occurring every three to six months, though individual timing depends on pellet dose, patient metabolism, and ongoing lab results.

The release rate is thought to be influenced by local blood flow to the implantation site. Physical activity and periods of increased cardiovascular demand may accelerate hormone uptake from the area slightly, creating a delivery pattern that tracks loosely with physiological activity rather than remaining entirely fixed. This remains a mechanistic explanation based on vascular physiology rather than a finding that has been rigorously tested in recent controlled trials specific to hormone pellets.

The foundational evidence for pellet kinetics comes from Clinical Endocrinology Oxford 1996, which studied subcutaneous testosterone implants in 14 hypogonadal men (detailed PK cohort) and 50 men total. The results showed that testosterone peaked sharply within the first half-day after implantation, then stabilized into a plateau phase lasting through approximately day 63—about two months. Hormone levels then declined gradually, with return to pre-treatment baseline by approximately day 300. The study also documented safety data: among 112 pellet implantations, 5.4% resulted in local infections, and five pellets extruded through the skin in three men.

This study is important as foundational pharmacokinetic evidence, but its limitations are real: it was conducted in 1996, involved only male hypogonadism patients, used a single pellet dose and size, and studied a small population. Comparative data against modern injection protocols, transdermal gels, or patches in diverse populations—including women—are not available in the current evidence base for this delivery method. The “3-6 months” duration frequently cited in clinical practice reflects clinical experience with current dosing protocols, not the plateau phase measured in the 1996 study.

How Pellet Kinetics Differ from Other Hormone Delivery Methods

Avoiding Peaks and Troughs: The Plateau Effect

One of the frequently cited advantages of pellet delivery is the reduction of hormone level fluctuations. Oral hormone formulations create predictable daily peaks shortly after ingestion and troughs in the hours before the next dose—fluctuations that many patients experience as energy swings, mood variability, or symptom recurrence between doses. Intramuscular testosterone injections create more pronounced early peaks in the 24 to 48 hours after administration, followed by gradual decline over one to two weeks. This injection cycle can leave patients feeling significantly better immediately after injection and noticeably worse in the days before the next one.

Research from Clinical Endocrinology Oxford 1996 demonstrates that after the initial half-day surge, subcutaneous testosterone implants maintained relatively stable serum levels through approximately the two-month mark before beginning a gradual decline. This pharmacokinetic profile avoids the sharp weekly oscillations of injection protocols. However, I want to be transparent about the evidence here: this study is nearly 30 years old, involved a small sample of men with hypogonadism, and did not compare pellets head-to-head against modern transdermal or subcutaneous injection protocols. The plateau effect is real and well-characterized in this foundational research, but claims of clear superiority over all other delivery methods cannot be made on the strength of current evidence alone.

Duration of Effect: 3-6 Month Release Window

Hormone pellets are designed to provide therapeutic hormone levels for three to six months, depending on pellet size, hormone dose, and individual patient metabolism. Mayo Clinic 2024 confirms this timeframe for testosterone pellets in the context of male hypogonadism treatment. The extended duration is the primary convenience advantage of pellet delivery—no daily pills, no weekly injections, no daily topical application. For patients managing demanding schedules, the reduction in treatment administration burden can be meaningful.

That said, the absence of daily administration also means the therapy cannot be quickly adjusted or stopped if side effects occur. Once inserted, the pellet will continue releasing hormone until fully dissolved—which may take several months. In my practice, I emphasize to patients that this irreversibility makes careful pre-treatment evaluation non-negotiable. Some patients metabolize pellets faster and may need re-insertion closer to the three-month mark; others maintain stable levels well into the six-month window. Ongoing lab work is the only reliable way to determine each patient’s individual pattern and optimal re-insertion timing.

Insertion Procedure and Pellet Composition

Pellet insertion is a minor in-office procedure performed under local anesthesia. A small incision—typically three to four millimeters—is made in the hip or buttock area, and the pellet or pellets are placed subcutaneously using a trocar instrument. The incision is closed with surgical tape or a single suture. In my practice, the entire procedure typically takes about 10 to 15 minutes, and most patients return to their normal activities the same day with minor activity restrictions for the first few days.

An essential part of the informed consent conversation is the regulatory status of these pellets. Hormone pellets used in the United States are compounded formulations—they are custom-made by compounding pharmacies and are not FDA-approved products. This distinction has real clinical significance. ACOG 2023 explicitly recommends “preparations other than pellet therapy” and cautions that compounded BHRT should not be prescribed routinely when FDA-approved formulations exist. The ACOG document also found that hormone dosing in compounded preparations can deviate significantly—up to 26% below label for estradiol and 31% above label for progesterone across different compounding pharmacies. Similarly, American Family Physician 2023 advises that “patients should be discouraged from seeking compounded bioidentical hormones, which are not regulated for safety or effectiveness.” These are the professional standards that frame how I discuss pellet therapy with every patient who asks about it.

Regulatory Context and Patient Selection Considerations

Understanding the regulatory landscape is not a deterrent to honest conversations about hormone therapy—it’s a prerequisite for them. Both ACOG 2023 and American Family Physician 2023 are clear: FDA-approved hormone formulations are the preferred first-line option when available, and compounded preparations—including pellets—should be reserved for patients with specific clinical needs that cannot be met by approved therapies. This guidance reflects the reality that compounded products have not undergone the standardized safety, efficacy, and quality control testing required for FDA approval.

The importance of safety monitoring came into sharp focus in 2019, when FDA 2019 revealed that during a 2018 inspection of BioTE Medical—a hormone pellet company—FDA investigators discovered approximately 4,202 adverse event reports collected between 2013 and 2018 that had never been submitted to the FDA as required. The reports involved potential associations with endometrial and prostate cancer, strokes, heart attacks, deep vein thrombosis, and pellet extrusion, though the FDA could definitively attribute only a portion of those reports to the pellets due to incomplete adverse event documentation. This case underscores why adverse event transparency and rigorous monitoring are not optional extras in pellet therapy—they are foundational to patient safety.

For patients who are appropriate candidates for physician-supervised hormone replacement therapy—those who have undergone comprehensive evaluation, who have been counseled on the compounded nature and regulatory status of pellets, who have not responded to or cannot tolerate FDA-approved delivery options, and who commit to ongoing lab monitoring—pellets can offer a clinically meaningful sustained-release profile. But pellet therapy is not a first-line option for most patients, and it is not appropriate for patients seeking hormone therapy without a clear clinical indication and thorough evaluation. Results vary by individual, and outcomes depend on your unique biology, hormone levels, and treatment history.

Hormone Optimization for Active Adults in Spring and North Houston

Whether you’re an active professional training along Spring Creek Greenway or managing family and career demands in The Woodlands, Tomball, or Kingwood, hormone-related symptoms can disrupt the lifestyle you’ve worked hard to build. I work with many patients from these communities who come in not because they’ve decided on a specific hormone delivery method, but because they’re experiencing symptoms—persistent fatigue, mood changes, difficulty maintaining muscle mass, or libido changes—that are affecting their quality of life and that haven’t resolved with lifestyle modifications alone.

For patients who have already tried other hormone delivery methods and experienced inconsistent results—symptom return between injections, skin irritation from patches, or variable absorption with topical gels—understanding how the pellet delivery mechanism differs is a reasonable part of an informed conversation. At Harmony Aesthetics Spa, I evaluate hormone therapy within the context of each patient’s complete metabolic health: body composition, cardiovascular risk profile, symptom history, lab values, and lifestyle demands. The goal is not simply to deliver hormone—it’s to optimize overall wellness in a way that is clinically appropriate, sustainable, and aligned with the patient’s long-term health. Our Spring location serves patients throughout the greater North Houston area, and every hormone evaluation begins with a conversation—not a predetermined delivery method.

When Is It Time to Talk to Dr. Crystal About Hormone Therapy Options?

Recognizing when hormone-related symptoms warrant a physician consultation is the first step. You may be ready to explore hormone therapy if you’re experiencing:

If you’ve tried other hormone delivery methods and experienced inconsistent results, side effects, or difficulty maintaining stable symptom relief between doses, a conversation about alternative delivery options—including pellets—may be appropriate. In my practice, I approach this as part of a comprehensive evaluation that includes your hormone panel, metabolic markers, health history, cardiovascular risk, and treatment goals. The decision to pursue pellet therapy is never made in isolation; it’s made collaboratively, with full transparency about what the science shows and what the current professional guidance says.

What to Expect During a Hormone Therapy Consultation at Harmony Aesthetics Spa

Your hormone therapy consultation at Harmony Aesthetics Spa begins with a detailed health history review. I want to understand your symptoms, how they’re affecting your daily life, what you’ve already tried, and what your treatment goals are. This is not a quick questionnaire—it’s a real conversation designed to help me understand your complete clinical picture before any therapy is recommended.

After our initial discussion, my clinical team will order comprehensive lab work to assess your current hormone levels—testosterone, estradiol, progesterone, thyroid panel, and metabolic markers. These baseline labs are essential. They tell me what’s actually happening hormonally, help identify whether any contraindications to pellet therapy are present, and give us an objective baseline to compare against when we follow up after treatment. Once labs are reviewed, I’ll discuss whether hormone therapy is appropriate for your situation, which delivery method best fits your clinical needs and lifestyle, and what realistic outcomes look like based on your individual profile.

If pellet therapy is recommended and you choose to proceed, I’ll explain the full insertion procedure, the expected timeline for symptom improvement, your monitoring schedule, and what to watch for in terms of side effects or complications. In my practice, I use the EvexiPEL bioidentical hormone pellet system—a compounded pellet formulated to each patient’s specific hormonal needs—as part of the range of delivery options I discuss with patients who are appropriate candidates for pellet therapy. The pellet insertion procedure takes about 10 to 15 minutes under local anesthesia; most patients find it straightforward and return to normal activities the same day. I schedule follow-up lab work typically at 4 to 6 weeks post-insertion to assess your hormone response, then every 3 to 6 months thereafter to guide re-insertion timing and any dose adjustments. The emphasis throughout is physician-supervised, individualized care—not a one-size-fits-all protocol.

Physician-Supervised Pellet Therapy vs. Non-Physician Hormone Services

One Patient’s Experience

At Harmony Aesthetics Spa, every patient interaction reflects the same commitment: warm, professional care that makes you feel genuinely supported through whatever part of your health journey you’re navigating.

Individual results may vary.

Branden’s experience reflects what I strive for every day: a team environment where patients feel encouraged and supported—not just processed through a treatment protocol. Whether you’re coming in for a first hormone consultation or a follow-up appointment, that warmth is what we bring to every visit.

Taking the First Step Toward Hormone Balance in Spring, TX

The hormone pellet delivery system offers a distinct pharmacokinetic profile: a brief initial surge followed by a more stable release phase, delivering hormone over a period of months without the sharp peaks and troughs of daily oral formulations or the weekly oscillations of intramuscular injections. That foundational mechanism is supported by clinical research. What the research also makes clear is that pellets are compounded formulations that have not received FDA approval, that major professional societies including ACOG and the AAFP recommend FDA-approved hormone therapies as the preferred option, and that pellet therapy requires careful patient selection, transparent informed consent, and ongoing monitoring to be used responsibly.

For patients across the greater North Houston area who are experiencing hormone-related symptoms, I believe the most important first step is a thorough, honest evaluation—not a commitment to any specific delivery method. Results vary by individual, and outcomes depend on your unique biology, hormone levels, and overall health history. My role is to help you understand your options, what the evidence actually shows, and which path forward makes the most sense for your clinical situation and your life. Schedule a hormone therapy consultation at Harmony Aesthetics Spa to begin that conversation. You can also call or text us at 346-597-1202.

Frequently Asked Questions